新闻 | 康伊纳公司（TenX）与Citius Pharmaceuticals签署合并协议
2023年10月23日，康伊纳公司（纳斯达克股票代码：TENK）与一家开发重症药物的生物制药公司Citius Pharma（纳斯达克股票代码：CTXR）签署业务合并协议，新成立的上市公司命名为Citius Oncology,Inc.（Citius Oncology），预计将于2024年上半年完成交易。
Citius Oncology是一家开发新型靶向肿瘤疗法药物平台公司，该公司的产品LYMPHIR用于治疗罕见的淋巴癌 - 持续性或复发性皮肤T细胞淋巴癌（CTCL），专家预计LYMPHIR的市场将超过4亿美元并会持续增长，LYMPHIR是唯一的靶向疗法，本产品预计将于2024年获得美国FDA的注册批准，2024年下半年进入市场用于治疗CTCL，为患者带来福音。
三八妇乐科技集团董事长、康伊纳公司董事长兼CEO袁晓峰表示：我们非常高兴地宣布与Citius Oncology的合并计划，在评估了众多潜在的标的公司后，我们董事会和管理层认为，此次与Citius Oncology的交易将会为我们的股东创造巨大的价值，如果这项业务合并得以完成，TenX的股东将会持股一家专注于开发治疗CTCL患者药物公司的股权，我们很高兴能在Citius Oncology发展的里程碑为其提供支持和途径。
国
际
版
TenX Keane Acquisition signed the merger agreement with Citius Pharmaceuticals
On 23 October 2023, TenX Keane Acquisition (NASDAQ: TENK) and Citius Pharma (NASDAQ: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, signed a business combination agreement for a newly formed public company named Citius Oncology, Inc.(“Citius Oncology”)，which is expected to complete the transaction in the first half of 2024.
Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapeutic drugs, whose product LYMPHIR is used for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. Experts estimate the initial market for LYMPHIR currently exceeds $400 million and will continue to grow.As the only targeted CTCL therapy, LYMPHIR is expected to receive registration approval from U.S. FDA in 2024, and enter the market for the treatment of CTCL in the second half of 2024, offering a novel option to patients.
“We are very pleased to announce the proposed merger with Citius Oncology,”said Mr.Xiaofeng Yuan, Chairman of Shaanxi 38fule Technology Group, Chairman and CEO of TenX. “After undertaking a comprehensive process to explore and evaluate numerous potential business combination targets, our board and management team believe that this transaction with Citius Oncology will create substantial value for our stockholders. This business combination, if consummated, will result in TenX investors owning an equity stake in a company that is focused on developing and commercializing LYMPHIR to improve the lives of patients with CTCL. We are thrilled to support Citius Oncology at an inflection point in its development and to provide an avenue for Citius to expeditiously meet its development milestones.”